<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: been due primarily", fill: "#009000"},
{source: "4: been due primarily", target: "4: expenditures", fill: "#009000"},
{source: "4: expenditures", target: "4: development on", fill: "#009000"},
{source: "4: development on", target: "4: administrative", fill: "#009000"},
{source: "4: administrative", target: "4: significant revenues", fill: "#009000"},
{source: "4: been due primarily", target: "6: three years", fill: "#66b032"},
{source: "6: three years", target: "6: possibly longer", fill: "#66b032"},
{source: "6: possibly longer", target: "6: generate recurring revenues", fill: "#66b032"},
{source: "6: generate recurring revenues", target: "6: development", fill: "#66b032"},
{source: "6: development", target: "6: current potential products", fill: "#66b032"},
{source: "6: current potential products", target: "6: marketing approvals", fill: "#66b032"},
{source: "6: three years", target: "13: financial resources", fill: "#138808"},
{source: "13: financial resources", target: "13: Contents ", fill: "#138808"},
{source: "13: Contents ", target: "13: operations", fill: "#138808"},
{source: "13: operations", target: "13: third quarter", fill: "#138808"},
{source: "13: third quarter", target: "13: dependent on", fill: "#138808"},
{source: "13: dependent on", target: "13: financing from third parties", fill: "#138808"},
{source: "13: financing from third parties", target: "13: Phase II ", fill: "#138808"},
{source: "13: Phase II ", target: "13: clinical program with", fill: "#138808"},
{source: "13: clinical program with", target: "13: arimoclomol", fill: "#138808"},
{source: "13: arimoclomol", target: "13: development efforts", fill: "#138808"},
{source: "13: development efforts", target: "13: candidates", fill: "#138808"},
{source: "13: candidates", target: "13: obligations", fill: "#138808"},
{source: "13: obligations", target: "13: no commitments from third parties", fill: "#138808"},
{source: "13: no commitments from third parties", target: "13: provide us with", fill: "#138808"},
{source: "13: provide us with", target: "13: additional debt", fill: "#138808"},
{source: "13: additional debt", target: "13: equity financing", fill: "#138808"},
{source: "13: equity financing", target: "13: financing on", fill: "#138808"},
{source: "13: financial resources", target: "15: appropriate company", fill: "#e3a857"},
{source: "15: appropriate company", target: "15: merge with", fill: "#e3a857"},
{source: "15: merge with", target: "15: could consummate such", fill: "#e3a857"},
{source: "15: could consummate such", target: "15: transaction on terms", fill: "#e3a857"},
{source: "15: transaction on terms", target: "15: stockholders", fill: "#e3a857"},
{source: "15: appropriate company", target: "27: internally fund", fill: "#ff0800"},
{source: "27: internally fund", target: "27: significant", fill: "#ff0800"},
{source: "27: significant", target: "27: development", fill: "#ff0800"},
{source: "27: development", target: "27: at least one", fill: "#ff0800"},
{source: "27: at least one", target: "27: candidates", fill: "#ff0800"},
{source: "27: candidates", target: "27: early stage development", fill: "#ff0800"},
{source: "27: early stage development", target: "27: certain product", fill: "#ff0800"},
{source: "27: certain product", target: "27: applications based on", fill: "#ff0800"},
{source: "27: applications based on", target: "27: technologies", fill: "#ff0800"},
{source: "27: technologies", target: "27: licensed from", fill: "#ff0800"},
{source: "27: licensed from", target: "27: later stage development", fill: "#ff0800"},
{source: "27: later stage development", target: "27: of the ALS ", fill: "#ff0800"},
{source: "27: of the ALS ", target: "27: completion", fill: "#ff0800"},
{source: "27: completion", target: "27: development manufacture", fill: "#ff0800"},
{source: "27: development manufacture", target: "27: enter into strategic alliances license agreements", fill: "#ff0800"},
{source: "27: enter into strategic alliances license agreements", target: "27: collaborative", fill: "#ff0800"},
{source: "27: collaborative", target: "27: arrangements with larger pharmaceutical", fill: "#ff0800"},
{source: "27: arrangements with larger pharmaceutical", target: "27: biotechnology companies", fill: "#ff0800"},
{source: "27: internally fund", target: "30: connection with", fill: "#746cc0"},
{source: "30: connection with", target: "30: technology", fill: "#746cc0"},
{source: "30: technology", target: "30: licensed from", fill: "#746cc0"},
{source: "30: licensed from", target: "30: Contents ", fill: "#746cc0"},
{source: "30: Contents ", target: "30: commercial relationship with", fill: "#746cc0"},
{source: "30: connection with", target: "38: such products", fill: "#915c83"},
{source: "38: such products", target: "38: difficult", fill: "#915c83"},
{source: "38: difficult", target: "38: financial resources", fill: "#915c83"},
{source: "38: financial resources", target: "38: products using", fill: "#915c83"},
{source: "38: products using", target: "38: securities as currency", fill: "#915c83"},
{source: "38: securities as currency", target: "38: shareholder dilution", fill: "#915c83"},
{source: "38: such products", target: "86: Depending ", fill: "#65000b"},
{source: "86: Depending ", target: "86: future financing activities", fill: "#65000b"},
{source: "86: future financing activities", target: "86: control with", fill: "#65000b"},
{source: "86: control with", target: "86: shareholders whose interests may", fill: "#65000b"},
{source: "86: shareholders whose interests may", target: "86: directly aligned with ours", fill: "#65000b"},
{source: "86: Depending ", target: "182: significant legal accounting", fill: "#e6e6fa"},
{source: "182: significant legal accounting", target: "182: compliance will occupy", fill: "#e6e6fa"},
{source: "182: compliance will occupy", target: "182: Contents ", fill: "#e6e6fa"},
{source: "182: Contents ", target: "182: directors", fill: "#e6e6fa"},
{source: "182: directors", target: "182: management", fill: "#e6e6fa"},
{source: "182: significant legal accounting", target: "START_HERE", fill: "#e6e6fa"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/INS_Kadamba">INS Kadamba</a></td>
      <td>INS Kadamba is an Indian Navy base located near Karwar in Karnataka. The first phase of construction of the base, code-named Project Seabird, was completed in 2005 and the base was commissioned on 31 May 2005.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MIM-23_Hawk">MIM-23 Hawk</a></td>
      <td>The Raytheon MIM-23 HAWK ("Homing All the Way Killer, commonly referred to as "Hawk") is an American medium-range surface-to-air missile. It was designed to be a much more mobile counterpart to the MIM-14 Nike Hercules, trading off range and altitude capability for a much smaller size and weight.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bhadla_Solar_Park">Bhadla Solar Park</a></td>
      <td>Bhadla Solar Park is the largest solar park in the world as of 2021, and is spread over a total area of 5,700 hectares (14,000 acres) in Bhadla, Phalodi tehsil, Jodhpur district, Rajasthan, India.The park has a total capacity of 2245 MW. The park had witnessed the lowest bid for solar power in India as of December 2020 at ₹2.44 (3.2¢ US) per kilowatt-hour. In September 2018, Acme Solar announced that it had commissioned India's cheapest solar power: 200 MW at Bhadla.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder">Shareholder</a></td>
      <td>A shareholder (in the United States often referred to as stockholder) of a corporation is an individual or legal entity (such as another corporation, a body politic, a trust or partnership) that is registered by the corporation as the legal owner of shares of the share capital of a public or private corporation. Shareholders may be referred to as members of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholders'_agreement">Shareholders' agreement</a></td>
      <td>A shareholders' agreement (sometimes referred to in the U.S. as a stockholders' agreement) (SHA) is an agreement amongst the shareholders or members of a company. In practical effect, it is analogous to a partnership agreement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Friedman_doctrine">Friedman doctrine</a></td>
      <td>The Friedman doctrine, also called shareholder theory or stockholder theory, is a normative theory of business ethics advanced by economist Milton Friedman which holds that the social responsibility of business is to increase its profits. This shareholder primacy approach views shareholders as the economic engine of the organization and the only group to which the firm is socially responsible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/L3Harris_Technologies">L3Harris Technologies</a></td>
      <td>L3Harris Technologies (L3Harris) is an American technology company, defense contractor, and information technology services provider that produces C6ISR systems and products, wireless equipment, tactical radios, avionics and electronic systems, night vision equipment, and both terrestrial and spaceborne antennas for use in the government, defense, and commercial sectors. They specialize in surveillance solutions, microwave weaponry, and electronic warfare.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Continental_Connection">Continental Connection</a></td>
      <td>Continental Connection was a brand name under which several commuter airline carriers and their holding companies operated services marketed exclusively by Continental Airlines. As such, all Continental Connection banner carrier services were operated primarily with turboprop aircraft in contrast to Continental Express, whose flights were operated by Continental's regional jet partners, ExpressJet Airlines and Chautauqua Airlines.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Connection_string">Connection string</a></td>
      <td>In computing, a connection string is a string that specifies information about a data source and the means of connecting to it. It is passed in code to an underlying driver or provider in order to initiate the connection.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Connection_pool">Connection pool</a></td>
      <td>In software engineering, a connection pool is a cache of database connections maintained so that the connections can be reused when future requests to the database are required.\nConnection pools are used to enhance the performance of executing commands on a database.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mothership_Connection">Mothership Connection</a></td>
      <td>Mothership Connection is the fourth album by American funk band Parliament, released on December 15, 1975 on Casablanca Records. This concept album is often rated among the best Parliament-Funkadelic releases, and was the first to feature horn players Maceo Parker and Fred Wesley, who had previously backed James Brown in the J.B.'s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_to_Cure">Difficult to Cure</a></td>
      <td>Difficult to Cure is the fifth studio album by the British hard rock band Rainbow, released in 1981. The album marked the further commercialization of the band's sound, with Ritchie Blackmore once describing at the time his appreciation of the band Foreigner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_People">Difficult People</a></td>
      <td>Difficult People is an American dark comedy streaming television series created by Julie Klausner.  Klausner stars alongside Billy Eichner as two struggling and jaded comedians living in New York City; the duo seemingly hate everyone but each other.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Healing_Is_Difficult">Healing Is Difficult</a></td>
      <td>Healing Is Difficult is the second studio album by Australian singer and songwriter Sia. It was released in the United Kingdom on 9 July 2001 and in the United States on 28 May 2002.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_Loves">Difficult Loves</a></td>
      <td>Difficult Loves (Italian: Gli amori difficili) is a 1970 short story collection by Italo Calvino. It concerns love and the difficulty of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Board_of_directors">Board of directors</a></td>
      <td>A board of directors (commonly referred simply as the board) is an executive committee that jointly supervises the activities of an organization, which can be either a for-profit or a nonprofit organization such as a business, nonprofit organization, or a government agency. \nThe powers, duties, and responsibilities of a board of directors are determined by government regulations (including the jurisdiction's corporate law) and the organization's own constitution and by-laws.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Directors'_Fortnight">Directors' Fortnight</a></td>
      <td>The Directors' Fortnight (French: Quinzaine des Réalisateurs) is an independent selection of the Cannes Film Festival. It was started in 1969 by the French Directors Guild after the events of May 1968 resulted in cancellation of the Cannes festival as an act of solidarity with striking workers.The Directors' Fortnight showcases a programme of shorts and feature films and documentaries worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Creative_director">Creative director</a></td>
      <td>A creative director (or creative supervisor) is a person that makes high-level creative decisions, and with those decisions oversees the creation of creative assets such as advertisements, products, events, or logos. Creative director positions are often found within the television production, graphic design, film, music, video game, fashion, advertising, media, or entertainment industries, but may be useful in other creative organizations such as web development and software development firms as well.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chief_executive_officer">Chief executive officer</a></td>
      <td>A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO), or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization –  especially an independent legal entity such as a company or nonprofit institution. CEOs find roles in a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (notably state-owned enterprises).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Film_director">Film director</a></td>
      <td>A film director controls a film's artistic and dramatic aspects and visualizes the screenplay (or script) while guiding the film crew and actors in the fulfilment of that vision. The director has a key role in choosing the cast members, production design and all the creative aspects of filmmaking.The film director gives direction to the cast and crew and creates an overall vision through which a film eventually becomes realized or noticed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Executive_director">Executive director</a></td>
      <td>An executive director is a member of a board of directors for an organisation, but the meaning of the term varies between countries.\n\n\n== United States ==\nIn the US, an executive director is a chief executive officer (CEO) or managing director of an organization, company, or corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Atlee_(director)">Atlee (director)</a></td>
      <td>Arun Kumar (born 21 September 1986), known mononymously as Atlee, is an Indian director who makes Tamil-language films. A former assistant director under S. Shankar on the films Enthiran (2010) and Nanban (2012), he is best known for his directorial debut, Raja Rani, produced by Fox Star Studios, for which he was awarded the Vijay Award for Best Debut Director.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bala_(director)">Bala (director)</a></td>
      <td>Balasubramanian known as Bala is an Indian film director, screenwriter, and producer, working in Tamil cinema. Often considered to be one of the finest directors in Tamil, Bala is widely acclaimed for "revolutionizing Tamil cinema" through his realistic, dark and disturbing depiction of the working class on celluloid screen.Just within directing a handful of films, his movies went on to win 6 National Awards, 13 State awards, 15 Filmfare Awards, 14 International Festival Awards and numerous coveted state awards which created a storm within the Indian movie scene.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CYTRX CORP      Item 1A Risk Factors          If any of the <font color="blue">following risks actually</font> occur, our business or prospects     could be <font color="blue"><font color="blue">materially</font> <font color="blue"><font color="blue">adversely affect</font>ed</font></font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should also refer</font> to the other     information in this Annual Report, including our <font color="blue">financial statements</font> and     the related notes</td>
    </tr>
    <tr>
      <td><font color="blue">We Have Operated </font>at a <font color="blue">Loss and Will Likely Continue to Operate </font>at a Loss For     the Foreseeable Future          We have <font color="blue">incurred <font color="blue">significant</font> losses over</font> the <font color="blue">past five years</font>, including     net losses of dlra15dtta1 million, dlra16dtta4 million and dlra17dtta8 million for the years     ended  <font color="blue">December </font>31,  2005,  2004 and 2003, respectively, and we had an     <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font> dlra121dtta3 million as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Our  operating  losses have <font color="blue">been due primarily</font> to our <font color="blue">expenditures</font> for     research and <font color="blue"><font color="blue">development</font> on</font> our products and for general and <font color="blue">administrative</font>     expenses and our lack of <font color="blue"><font color="blue">significant</font> revenues</font></td>
    </tr>
    <tr>
      <td>We are likely to continue to     incur  operating  losses  until  such  time, if ever, that we generate     <font color="blue"><font color="blue"><font color="blue">significant</font> recurring</font> revenues</font></td>
    </tr>
    <tr>
      <td>We anticipate it will take a minimum of     <font color="blue">three years</font> (and <font color="blue">possibly longer</font>) for us to <font color="blue">generate recurring revenues</font>,     since we expect that it will take at least that long before the <font color="blue">development</font>     of any of our licensed or other <font color="blue">current <font color="blue">potential products</font></font> is completed,     <font color="blue">marketing approvals</font> are obtained from the FDA and commercial sales of any of     these products can begin</td>
    </tr>
    <tr>
      <td>We  Have  No  Source of Significant Recurring Revenues, Which Makes Us     Dependent on Financing to Sustain Our Operations          Our revenues were dlra184cmam000, dlra428cmam000, and dlra94cmam000 during the years     ended <font color="blue">December </font>31, 2005, 2004 and 2003, respectively</td>
    </tr>
    <tr>
      <td>We will not have     <font color="blue"><font color="blue">significant</font> recurring</font> operating <font color="blue">revenues until <font color="blue">at least one</font></font> of the following     occurs:       •   We are able to complete the <font color="blue">development</font> of and <font color="blue">commercialize one</font> or     more of the products that we are currently developing, which may require us     to <font color="blue">first <font color="blue">enter into</font> license</font> or other <font color="blue"><font color="blue"><font color="blue">arrangement</font>s</font> with <font color="blue">third parties</font></font></td>
    </tr>
    <tr>
      <td>•   One or more of our currently licensed products is <font color="blue">commercialized</font> by     our licensees, thereby <font color="blue">generating</font> royalty income for us</td>
    </tr>
    <tr>
      <td>•   We are able to acquire <font color="blue">products from <font color="blue">third parties</font></font> that are already     being marketed or are approved for marketing</td>
    </tr>
    <tr>
      <td>We expect to <font color="blue">incur losses from <font color="blue">operations</font> until such</font> time, if ever, as     we  can  generate <font color="blue"><font color="blue"><font color="blue">significant</font> recurring</font> revenues</font></td>
    </tr>
    <tr>
      <td>On March 7, 2006, we     completed  a  <font color="blue">private placement financing</font> and received net proceeds of     <font color="blue">approximately</font> dlra12dtta4 million</td>
    </tr>
    <tr>
      <td>Although we believe that we have adequate     <font color="blue">financial resources</font> to support our                                         12       _________________________________________________________________    [57]Table of <font color="blue">Contents       </font>currently planned level of <font color="blue">operations</font> into the <font color="blue">third quarter</font> of 2007, we     will be <font color="blue"><font color="blue">dependent</font> on</font> obtaining <font color="blue">financing from <font color="blue">third parties</font></font> in order to     maintain  our <font color="blue">operations</font>, including our <font color="blue">Phase II </font><font color="blue"><font color="blue">clinical program</font> with</font>     <font color="blue">arimoclomol</font> for ALS, our planned levels of <font color="blue">operations</font> for our obesity and     type 2 diabetes <font color="blue">laboratory</font>, our planned RNAi subsidiary and our ongoing     research and <font color="blue">development</font> efforts related to our other small molecule drug     <font color="blue">candidates</font>, and in order to continue to meet our <font color="blue">obligations</font> to UMMS          We  have <font color="blue">no <font color="blue">commitments</font> from <font color="blue">third parties</font></font> to <font color="blue">provide us with</font> any     <font color="blue"><font color="blue">additional</font> debt</font> or <font color="blue">equity financing</font>, and may not be able to obtain future     <font color="blue">financing on</font> favorable terms, or at all</td>
    </tr>
    <tr>
      <td>A lack of needed <font color="blue">financing would</font>     force us to reduce the scope of, or terminate, our <font color="blue">operations</font>, or to seek to     <font color="blue">merge with</font> or to be acquired by another company</td>
    </tr>
    <tr>
      <td>There can be no assurance     that we would be able to identify an <font color="blue">appropriate company</font> to <font color="blue">merge with</font> or be     acquired by or that we <font color="blue">could consummate such</font> a <font color="blue"><font color="blue">transaction</font> on terms</font> that     would be attractive to our <font color="blue">stockholders</font> or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Most of Our Revenues Have Been Generated </font>by License Fees for TranzFect,     Which May Not be a Recurring Source of Revenue for Us          License fees paid to <font color="blue">us with respect</font> to our TranzFect <font color="blue">technology</font> have     represented 54prca, 93prca and 81prca of our <font color="blue">total revenues</font> for the years ended     <font color="blue">December </font>31, 2005, 2004 and 2003, respectively</td>
    </tr>
    <tr>
      <td>We have <font color="blue">already licensed</font>     most of the <font color="blue">potential <font color="blue">applications</font></font> for this <font color="blue">technology</font>, and there can be no     assurance that we will be able to <font color="blue">generate <font color="blue">additional</font> license fee revenues</font>     from  any <font color="blue">new licensees</font> for this <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">current licensees</font> for     TranzFect, Merck, and Vical, may be required to make <font color="blue">further milestone</font>     payments to us under their <font color="blue">licenses <font color="blue">based on</font></font> their future <font color="blue">development</font> of     <font color="blue">products using</font> TranzFect</td>
    </tr>
    <tr>
      <td>Since TranzFect is to be used as a component in     vaccines, we do not need to seek FDA approval, but any <font color="blue">vaccine <font color="blue">manufacture</font>r</font>     will need to seek FDA approval for the <font color="blue">final vaccine <font color="blue">formulation</font> containing</font>     TranzFect</td>
    </tr>
    <tr>
      <td>Merck has completed a multi-center, blinded, placebo controlled     Phase I trial of an HIV <font color="blue">vaccine utilizing</font> TranzFect as a component</td>
    </tr>
    <tr>
      <td>In the     Merck trials, although the <font color="blue">formulation</font> of the <font color="blue">tested vaccine using</font> TranzFect     was generally safe, well-tolerated and generated an <font color="blue">immune response</font>, the     addition of TranzFect to the vaccine did not increase this <font color="blue">immune response</font></td>
    </tr>
    <tr>
      <td>Moreover, the DNA single-modality vaccine regimen with TranzFect, when     tested in humans, yielded <font color="blue">immune response</font>s that were inferior to those     obtained with the DNA vaccines in <font color="blue">macaque monkeys</font></td>
    </tr>
    <tr>
      <td>Accordingly, there is     likely to be a substantial period of time, if ever, before we receive any     <font color="blue">further <font color="blue">significant</font> payments from</font> <font color="blue">Merck or Vical </font>under their TranzFect     licenses</td>
    </tr>
    <tr>
      <td>We Have Changed Our Business Strategy, Which Will Require Us, in Certain     Cases,  to Find and Rely Upon Third Parties for the Development of Our     Products and to Provide Us With Products          Following our <font color="blue">merger with</font> Global Genomics, we modified our business     strategy  of <font color="blue">internally</font> developing Flocor and the other, then-current,     <font color="blue">potential products</font> that we had not yet licensed to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Instead,     we began to seek to <font color="blue">enter into</font> strategic alliances, license <font color="blue"><font color="blue">agreement</font>s</font> or     other <font color="blue"><font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> with</font> other <font color="blue"><font color="blue">pharmaceutical</font> companies</font> that     <font color="blue">would provide</font> for those companies to be responsible for the <font color="blue">development</font> and     marketing of those products</td>
    </tr>
    <tr>
      <td>In June 2004, we licensed Flocor, the primary     potential product that we held prior to the <font color="blue">Global Genomics </font>merger and which     we had not <font color="blue">already licensed</font> to a <font color="blue">third party</font>, to SynthRx, Inc, a recently     formed Houston, Texas-based bio<font color="blue">pharmaceutical</font> company, under a strategic     alliance that we <font color="blue">entered into with</font> that company in October 2003</td>
    </tr>
    <tr>
      <td>Although we     intend to <font color="blue">internally</font> fund or carry out a <font color="blue">significant</font> portion of the research     and  <font color="blue">development</font>  related  to  <font color="blue">at least one</font> of our small molecule drug     <font color="blue">candidates</font>,  and  the <font color="blue">early stage</font> <font color="blue">development</font> work for <font color="blue">certain product</font>     <font color="blue"><font color="blue">applications</font> <font color="blue">based on</font></font> the RNAi and other <font color="blue">technologies</font> that we <font color="blue">licensed from</font>     UMMS, and we may seek to fund all of the later stage <font color="blue">development</font> work for     our potential ALS products, the <font color="blue">completion</font> of the <font color="blue">development</font>, <font color="blue">manufacture</font>     and marketing of these products is likely to require, in many cases, that we     <font color="blue">enter into</font> strategic alliances, license <font color="blue"><font color="blue">agreement</font>s</font> or other <font color="blue">collaborative</font>     <font color="blue"><font color="blue"><font color="blue">arrangement</font>s</font> with larger <font color="blue">pharmaceutical</font></font> or bio<font color="blue">technology</font> companies for this     purpose</td>
    </tr>
    <tr>
      <td>There can be no assurance that any of our <font color="blue">products will</font> have sufficient     <font color="blue">potential commercial value</font> to <font color="blue">enable us</font> to <font color="blue">secure strategic alliances</font>,     license  <font color="blue"><font color="blue">agreement</font>s</font>  or other <font color="blue"><font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font> with</font> suitable     <font color="blue">companies on attractive terms</font> or at all</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">enter into</font>     <font color="blue">collaborative</font> <font color="blue"><font color="blue">agreement</font>s</font>, we may not have the financial or other resources     to continue <font color="blue">development</font> of a <font color="blue">particular product</font> or the <font color="blue">development</font> of any of     our products</td>
    </tr>
    <tr>
      <td>In <font color="blue"><font color="blue">connection</font> with</font> the recently-completed Phase I clinical     trial conducted by UMMS and Advanced BioScience Laboratories on an HIV     vaccine candidate that utilizes a <font color="blue">technology</font> that we <font color="blue">licensed from</font> UMMS, we     do not have a                                         13       _________________________________________________________________    [58]Table of <font color="blue">Contents       </font><font color="blue">commercial relationship with</font> the company that provided an adjuvant for the     vaccine for the trial</td>
    </tr>
    <tr>
      <td>If we are not able to <font color="blue">enter into</font> an <font color="blue"><font color="blue">agreement</font> with</font>     this <font color="blue">company on terms</font> favorable to us or at all, we may be unable to use     some or all of the results of the <font color="blue">clinical trial</font> as part of our clinical     data  for obtaining FDA approval of this vaccine, <font color="blue">which will</font> delay the     <font color="blue">development</font> of the vaccine</td>
    </tr>
    <tr>
      <td>If we <font color="blue">enter into</font> these <font color="blue">collaborative</font> <font color="blue"><font color="blue">arrangement</font>s</font>, we will be <font color="blue">dependent</font>     upon the <font color="blue">timeliness</font> and <font color="blue"><font color="blue">effective</font>ness</font> of the <font color="blue">development</font> and marketing     efforts of our <font color="blue">contractual partners</font></td>
    </tr>
    <tr>
      <td>If these companies do not allocate     sufficient  personnel  and  resources  to  these  efforts or encounter     <font color="blue"><font color="blue">difficult</font>ies</font>  in  <font color="blue"><font color="blue">complying with</font> applicable <font color="blue">regulatory</font></font> (including FDA)     <font color="blue">requirements</font>,  the  timing of receipt or amount of <font color="blue">revenues from</font> these     <font color="blue"><font color="blue"><font color="blue">arrangement</font>s</font> may</font> be <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>By <font color="blue">entering into</font>     these <font color="blue"><font color="blue"><font color="blue">arrangement</font>s</font> rather than</font> completing the <font color="blue">development</font> and <font color="blue">then marketing</font>     these products on our own, we may suffer a reduction in the <font color="blue">ultimate overall</font>     <font color="blue">profitability</font> for us of these products</td>
    </tr>
    <tr>
      <td>In addition, if we are unable to     <font color="blue">enter into</font> these <font color="blue"><font color="blue">arrangement</font>s</font> for a <font color="blue">particular product</font>, we may be required     to <font color="blue">either sell</font> our rights in the product to a <font color="blue">third party</font> or abandon it     unless we are able to <font color="blue">raise sufficient capital</font> to fund the substantial     <font color="blue">expenditures</font> necessary for <font color="blue">development</font> and marketing of the product</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also seek</font> to acquire <font color="blue">products from <font color="blue">third parties</font></font> that already     are  being  marketed or have <font color="blue">previously been marketed</font></td>
    </tr>
    <tr>
      <td>Even if we do identify <font color="blue">such products</font>, it     may be <font color="blue">difficult</font> for us to acquire them with our limited <font color="blue">financial resources</font>     and, if we acquire <font color="blue">products using</font> our <font color="blue">securities as currency</font>, we may incur     substantial <font color="blue">shareholder dilution</font></td>
    </tr>
    <tr>
      <td>We do not have any prior experience in     acquiring or marketing products and may need to find <font color="blue">third parties</font> to market     these products for us</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also seek</font> to acquire <font color="blue">products through</font> a merger     with one or more companies that own <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>In any such merger, the     owners of our merger partner could be issued or hold a substantial, or even     <font color="blue">controlling</font>, amount of stock in our company or, in the event that the other     company is the <font color="blue">surviving company</font>, in that other company</td>
    </tr>
    <tr>
      <td>Our Current Financial Resources May Limit Our Ability to Execute Certain     Strategic Initiatives          In June 2004, we licensed Flocor to SynthRx, <font color="blue">which will</font> be responsible     for developing <font color="blue">potential product <font color="blue">applications</font></font> for Flocor</td>
    </tr>
    <tr>
      <td>Although we are     not doing any further <font color="blue">development</font> work on TranzFect or Flocor, should our     <font color="blue">three principal licensees</font> for those <font color="blue">technologies</font> <font color="blue">successfully</font> meet the     <font color="blue">defined <font color="blue">milestones</font></font>, we could receive future <font color="blue">milestone payments</font> and, should     any of the <font color="blue">licensees commercialize products based upon</font> our <font color="blue">technology</font>,     future  royalty  payments</td>
    </tr>
    <tr>
      <td>However, there can be no assurance that our     <font color="blue">licensees will continue</font> to develop or <font color="blue">ever commercialize</font> any products that     are <font color="blue">based on</font> our Flocor or our TranzFect <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our  strategic  alliance  with  UMMS will require us to make     <font color="blue">significant</font>  <font color="blue">expenditures</font>  to  fund  research  at UMMS relating to the     <font color="blue">development</font> of therapeutic products <font color="blue">based on</font> UMMS’s <font color="blue">technologies</font> that we     have licensed and pursuant to our <font color="blue">collaboration</font> and <font color="blue">invention disclosure</font>     <font color="blue">agreement</font>  with  UMMS  We estimate that the <font color="blue">aggregate amount</font> of these     <font color="blue">expenditures</font>  under  our  current  <font color="blue">commitments</font>  will  be <font color="blue">approximately</font>     dlra1cmam186cmam000 million for 2006 and <font color="blue">approximately</font> dlra450cmam000 for 2007</td>
    </tr>
    <tr>
      <td>Our license     <font color="blue"><font color="blue">agreement</font>s</font> with UMMS <font color="blue">also provide</font>, in <font color="blue">certain cases</font>, for <font color="blue">milestone payments</font>     <font color="blue">based on</font> the progress we make in the clinical <font color="blue">development</font> and marketing of     <font color="blue">products utilizing</font> the licensed <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In the event that we were to     <font color="blue">successfully</font> develop a product in each of the <font color="blue">categories</font> of obesity/type 2     diabetes, ALS, CMV and an HIV vaccine, under our licenses, those milestone     <font color="blue">payments could aggregate up</font> to dlra16dtta1 million</td>
    </tr>
    <tr>
      <td>We estimate that the <font color="blue">Phase II </font><font color="blue"><font color="blue">clinical program</font> with</font> <font color="blue">arimoclomol</font>     for ALS, including the recently-initiated <font color="blue">Phase IIa </font>trial and the <font color="blue"><font color="blue">Phase IIb </font>    </font>trial that we expect to <font color="blue">initiate soon</font> after <font color="blue">completion</font> of the present Phase     IIa trial subject to FDA approval, will require us to expend <font color="blue">approximately</font>     dlra17dtta8 million over a period of 24 to 30 months</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">agreement</font>     pursuant to which we acquired the clinical and <font color="blue"><font color="blue">pharmaceutical</font> assets</font> of     Biorex provides for <font color="blue">milestone payments</font> <font color="blue">based on</font> the occurrence of certain     <font color="blue"><font color="blue">regulatory</font> filings</font> and approvals related to the acquired products</td>
    </tr>
    <tr>
      <td>In the     event that we <font color="blue">successfully</font> develop any of the products acquired from Biorex,     the <font color="blue">milestone payments</font> could aggregate up to dlra4dtta2 million</td>
    </tr>
    <tr>
      <td>Each of the     foregoing <font color="blue">milestone payments</font>, however, could vary <font color="blue">significant</font>ly based upon     the <font color="blue">milestones</font> we achieve and the number of products we ultimately undertake     to develop</td>
    </tr>
    <tr>
      <td>Under our license for our HIV vaccine candidate, following the     <font color="blue">completion</font> of the current Phase I trial, we will be responsible for all of     the costs for <font color="blue">subsequent <font color="blue"><font color="blue">clinical trial</font>s</font></font> for this vaccine</td>
    </tr>
    <tr>
      <td>The costs of     <font color="blue">subsequent trials</font> for                                         14       _________________________________________________________________    [59]Table of <font color="blue">Contents       </font>the HIV <font color="blue">vaccine will</font> be very substantial</td>
    </tr>
    <tr>
      <td>Although we are seeking NIH or     other <font color="blue">governmental</font> funding for these future trials, we do not have, and     there can be no assurance that we will be able to secure, such funding for     any of these trials</td>
    </tr>
    <tr>
      <td>The <font color="blue">expenditures</font> <font color="blue">potentially</font> required under our <font color="blue"><font color="blue">agreement</font>s</font> with     UMMS  and ABL, <font color="blue">together with</font> the operating capital <font color="blue">requirements</font> of our     obesity and type 2 diabetes <font color="blue">laboratory</font>, our planned <font color="blue">sponsored research</font>     funding for Massachusetts General Hospital, our <font color="blue">Phase II </font><font color="blue">clinical program</font>     with <font color="blue">arimoclomol</font> for ALS and our <font color="blue">development</font> of our small molecule drug     <font color="blue">candidates</font>, <font color="blue">substantially</font> exceed our current <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Although  </font>   </font>we raised <font color="blue">approximately</font> dlra12dtta4 million in March 2006, net of <font color="blue">transaction</font>     expenses, those required <font color="blue">expenditures</font> will nonetheless require us to raise     <font color="blue"><font color="blue">additional</font> capital</font> or to secure a licensee or <font color="blue">strategic partner</font> in order to     maintain  our <font color="blue">operations</font>, including our <font color="blue">Phase II </font><font color="blue"><font color="blue">clinical program</font> with</font>     <font color="blue">arimoclomol</font> for ALS, our planned levels of <font color="blue">operations</font> for our obesity and     type 2 diabetes <font color="blue">laboratory</font>, our planned RNAi subsidiary and our ongoing     research and <font color="blue">development</font> efforts related to our other small molecule drug     <font color="blue">candidates</font>, and in order to continue to meet our <font color="blue">obligations</font> to UMMS If we     are  unable  to  meet  our various financial <font color="blue">obligations</font> under license     <font color="blue"><font color="blue">agreement</font>s</font>  with  UMMS,  we  could  lose all of our <font color="blue">rights under</font> those     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>If we were to have inadequate <font color="blue">financial resources</font> at that time,     we also could be forced to reduce the level of, or discontinue, <font color="blue">operations</font>     at our <font color="blue">laboratory</font></td>
    </tr>
    <tr>
      <td>If Our Products Are Not Successfully Developed and Approved by the FDA, We     May Be Forced to Reduce or Terminate Our Operations          All of our products are at various stages of <font color="blue">development</font> and must be     <font color="blue">approved by</font> the FDA or similar foreign <font color="blue">governmental</font> agencies before they can     be marketed</td>
    </tr>
    <tr>
      <td>The process for obtaining FDA approval is both time-consuming     and  costly,  with  <font color="blue">no certainty</font> of a <font color="blue">successful outcome</font></td>
    </tr>
    <tr>
      <td>This process     typically  includes the conduct of extensive pre-clinical and clinical     testing,  which  may take longer or cost more than we or our licensees     anticipate, and <font color="blue">may prove <font color="blue">unsuccessful</font> due</font> to <font color="blue">numerous factors</font></td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font><font color="blue">candidates</font> that may appear to be <font color="blue">promising at <font color="blue">early stage</font>s</font> of <font color="blue">development</font>     may not <font color="blue">successfully</font> reach the market for a number of reasons</td>
    </tr>
    <tr>
      <td>The results     of  preclinical and <font color="blue">initial <font color="blue">clinical testing</font></font> of these <font color="blue">products may</font> not     <font color="blue">necessarily indicate</font> the results that will be obtained from later or more     extensive  testing</td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>in the <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font>     <font color="blue">industries</font> have suffered <font color="blue">significant</font> setbacks in <font color="blue">advanced <font color="blue"><font color="blue">clinical trial</font>s</font></font>,     even after obtaining promising results in <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>Numerous <font color="blue">factors <font color="blue">could affect</font></font> the timing, cost or outcome of our drug     <font color="blue">development</font> efforts, including the following:       •   <font color="blue">Difficulty </font>in securing centers to conduct trials</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Difficulty </font>in enrolling patients in <font color="blue">conformity</font> with required protocols     or projected timelines</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Unexpected </font><font color="blue">adverse reactions by patients</font> in trials</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Difficulty </font>in obtaining <font color="blue">clinical supplies</font> of the product</td>
    </tr>
    <tr>
      <td>•   Changes in the FDA’s <font color="blue">requirements</font> for our testing during the course of     that testing</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Inability </font>to generate <font color="blue">statistically</font> <font color="blue">significant</font> data <font color="blue">confirming</font> the     efficacy of the product being tested</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Modification </font>of the <font color="blue">drug during testing</font></td>
    </tr>
    <tr>
      <td>•   <font color="blue">Reallocation </font>of our limited financial and other resources to other     <font color="blue">clinical program</font>s</td>
    </tr>
    <tr>
      <td>It is possible that none of the products we develop will obtain the     <font color="blue">appropriate <font color="blue"><font color="blue">regulatory</font> approval</font>s necessary</font> for us to <font color="blue">begin selling them</font></td>
    </tr>
    <tr>
      <td>The     time required to obtain FDA and other approvals is <font color="blue">unpredictable but often</font>     can take <font color="blue">years following</font> the <font color="blue">commencement</font> of <font color="blue"><font color="blue">clinical trial</font>s</font>, depending upon     the <font color="blue">complexity</font> of the <font color="blue">drug candidate</font></td>
    </tr>
    <tr>
      <td>Any analysis we perform of data from     clinical  <font color="blue">activities</font>  is subject to <font color="blue">confirmation</font> and <font color="blue">interpretation by</font>     <font color="blue">regulatory</font> authorities, <font color="blue">which could</font> delay, limit or <font color="blue">prevent <font color="blue">regulatory</font></font>     approval</td>
    </tr>
    <tr>
      <td>Any delay or failure in obtaining required                                         15       _________________________________________________________________    [60]Table of <font color="blue">Contents       </font><font color="blue">approvals could</font> have a material adverse effect on our ability to generate     revenues  from  the  particular <font color="blue">drug candidate</font> and we may not have the     <font color="blue">financial resources</font> to continue to develop our products and may have to     terminate our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Approach We Are Taking to Discover and Develop Novel Therapeutics Using     RNAi is Unproven and May Never Lead to Marketable Products          The RNAi <font color="blue">technologies</font> that we have acquired from UMMS have not yet been     clinically tested by us, nor are we aware of any <font color="blue"><font color="blue">clinical trial</font>s</font> having been     completed by <font color="blue">third parties</font> involving similar <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Neither we nor     any other company has received <font color="blue"><font color="blue">regulatory</font> approval</font> to <font color="blue">market <font color="blue">therapeutics</font></font>     utilizing RNAi</td>
    </tr>
    <tr>
      <td>The <font color="blue">scientific <font color="blue">discoveries</font></font> that form the basis for our     efforts to discover and develop new drugs are <font color="blue">relatively new</font></td>
    </tr>
    <tr>
      <td>The scientific     evidence to support the <font color="blue">feasibility</font> of developing drugs <font color="blue">based on</font> these     <font color="blue">discoveries</font> is <font color="blue">both preliminary</font> and limited</td>
    </tr>
    <tr>
      <td><font color="blue">Successful </font><font color="blue">development</font> of     RNAi-based <font color="blue">products will</font> require solving a number of issues, including     providing  suitable  methods of <font color="blue">stabilizing</font> the RNAi drug material and     delivering  it <font color="blue">into target cells</font> in the human body</td>
    </tr>
    <tr>
      <td>We may spend large     amounts of <font color="blue">money trying</font> to solve these issues, and never succeed in doing     so</td>
    </tr>
    <tr>
      <td>In addition, any compounds that we develop may not <font color="blue">demonstrate</font> in     patients the chemical and <font color="blue">pharmacological properties ascribed</font> to them in     <font color="blue">laboratory</font> studies, and they <font color="blue">may interact with human biological systems</font> in     unforeseen, in<font color="blue">effective</font> or <font color="blue">harmful ways</font></td>
    </tr>
    <tr>
      <td>Our Planned RNAi Subsidiary May Not Be Able to Obtain Sufficient Funding,     and We May Not Control a Majority of the Planned Subsidiary if We Obtain     Financing          We  are  currently  pursuing  a  plan to transfer all of our RNAi     <font color="blue">therapeutics</font>  assets  into a newly-formed subsidiary to <font color="blue">accelerate</font> the     <font color="blue">development</font>  and  <font color="blue">commercialization</font> of drugs <font color="blue">based on</font> RNAi <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  believe that this <font color="blue">structure may facilitate</font> our obtaining     <font color="blue"><font color="blue">additional</font> financing</font> to pursue our RNAi <font color="blue">development</font> efforts, we have no     <font color="blue">commitments</font> or <font color="blue"><font color="blue">arrangement</font>s</font> for any financing, and there is no assurance     that we will be able to obtain financing for this purpose</td>
    </tr>
    <tr>
      <td>Our planned RNAi     <font color="blue">subsidiary will</font> be <font color="blue">only partially</font> owned by us</td>
    </tr>
    <tr>
      <td><font color="blue">Depending </font>upon the amount and     terms of its future financing <font color="blue">activities</font>, we may not control the subsidiary,     or may share <font color="blue">control with</font> other <font color="blue">shareholders whose interests may</font> not be     <font color="blue">directly aligned with ours</font></td>
    </tr>
    <tr>
      <td>It also is possible that any products developed     by the RNAi <font color="blue">subsidiary could eventually compete with</font> our products for some     disease <font color="blue"><font color="blue">indication</font>s</font>, such as ALS, type 2 diabetes and obesity</td>
    </tr>
    <tr>
      <td><font color="blue">The Drug Candidates Acquired </font>from Biorex May Not Obtain Regulatory Marketing     Approvals          On October 4, 2004, we acquired all of the clinical and <font color="blue">pharmaceutical</font>     assets and related <font color="blue"><font color="blue">intellectual</font> property</font> of Biorex, including <font color="blue">three drug</font>     <font color="blue">candidates</font> (<font color="blue">arimoclomol</font>, iroxanadine and bimoclomol), and a library of small     molecule drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Although each of <font color="blue">arimoclomol</font>, iroxanadine and     bimoclomol has undergone <font color="blue">clinical testing</font>, <font color="blue">significant</font> and <font color="blue">costly <font color="blue">additional</font></font>     <font color="blue">testing will</font> be required in order to bring any product to market</td>
    </tr>
    <tr>
      <td>We may be     unable to confirm in our pre-clinical or <font color="blue"><font color="blue">clinical trial</font>s</font> with <font color="blue">arimoclomol</font>,     iroxanadine  or bimoclomol the favorable pre-clinical or <font color="blue">clinical data</font>     <font color="blue">previously generated by</font> European <font color="blue">investigators</font> for these drug <font color="blue">candidates</font>,     <font color="blue">which could</font> require us to have to modify our <font color="blue">development</font> plans for these     compounds</td>
    </tr>
    <tr>
      <td>In  <font color="blue">September </font>2005,  we  initiated  <font color="blue">Phase II </font><font color="blue">clinical testing</font> for     <font color="blue">arimoclomol</font> for ALS There are <font color="blue">no assurances</font> that the clinical <font color="blue">testing will</font>     be successful, or that the FDA <font color="blue">will permit us</font> to commence our planned Phase     IIb <font color="blue"><font color="blue">clinical trial</font> upon</font> the <font color="blue">completion</font> of our ongoing <font color="blue">Phase IIa </font>clinical     trial</td>
    </tr>
    <tr>
      <td>Any <font color="blue">additional</font> <font color="blue">requirements</font> imposed by the FDA in <font color="blue"><font color="blue">connection</font> with</font> the     ongoing <font color="blue">Phase IIa </font>trial, or in <font color="blue"><font color="blue">connection</font> with</font> our planned <font color="blue">Phase IIb </font>trial,     <font color="blue">could add further</font> time and expense for us to carry out this trial</td>
    </tr>
    <tr>
      <td>We believe that the FDA may accept the <font color="blue">completion</font> of a successful Phase     II  clinical  program  <font color="blue">as sufficient</font> to <font color="blue">enable us</font> to submit a New Drug     Application, or NDA; <font color="blue">however there</font> are <font color="blue">no assurances</font> that the FDA will     accept our <font color="blue">Phase II </font>program in lieu of a <font color="blue">Phase III </font><font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>If the     FDA  requires  us  to complete a <font color="blue">Phase III </font><font color="blue">clinical trial</font>, the cost of     <font color="blue">development</font> of <font color="blue">arimoclomol</font> will increase <font color="blue">significant</font>ly beyond our estimated     costs, and the time to <font color="blue">completion</font> of <font color="blue"><font color="blue">clinical testing</font> would</font> be delayed</td>
    </tr>
    <tr>
      <td>In     addition, the FDA <font color="blue">ultimately could</font> require us to achieve an efficacy end     point in the <font color="blue"><font color="blue">clinical trial</font>s</font> for <font color="blue">arimoclomol</font> that could be more <font color="blue">difficult</font>,     expensive and time-consuming                                         16       _________________________________________________________________    [61]Table of <font color="blue">Contents       </font>than our planned end point</td>
    </tr>
    <tr>
      <td>Although we anticipate developing <font color="blue">arimoclomol</font>     for the treatment of ALS, <font color="blue">arimoclomol</font> has <font color="blue">also shown therapeutic efficacy</font> in     a <font color="blue">preclinical animal model</font> of diabetes and we may pursue <font color="blue">development</font> of     <font color="blue">arimoclomol</font>  for <font color="blue">diabetic <font color="blue"><font color="blue">indication</font>s</font></font></td>
    </tr>
    <tr>
      <td>However, such <font color="blue">development</font> would     require <font color="blue">significant</font> and <font color="blue">costly <font color="blue">additional</font></font> testing</td>
    </tr>
    <tr>
      <td>There is no guarantee     that <font color="blue">arimoclomol</font> would show any efficacy for any other <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>Iroxanadine has <font color="blue">been tested</font> in two Phase I <font color="blue"><font color="blue">clinical trial</font>s</font> and one     Phase  II  clinical  <font color="blue">trial which showed improvement</font> in the function of     <font color="blue">endothelial cells</font> in <font color="blue">blood vessels</font> of <font color="blue"><font color="blue">patients at</font> risk</font> of <font color="blue">cardiovascular</font>     disease</td>
    </tr>
    <tr>
      <td>We  intend  to  develop  this product to <font color="blue">improve endothelial</font>     <font color="blue">dysfunction</font> in <font color="blue"><font color="blue">indication</font>s</font> such as diabetic retinopathy and <font color="blue">wound healing</font>,     <font color="blue">which will</font> require <font color="blue">significant</font> and <font color="blue">costly <font color="blue">additional</font></font> testing</td>
    </tr>
    <tr>
      <td>There is no     guarantee that iroxanadine will show any efficacy in the <font color="blue">intended uses</font> we     are  seeking</td>
    </tr>
    <tr>
      <td>We  may  also  attempt to license iroxanadine to larger     <font color="blue">pharmaceutical</font> or bio<font color="blue">technology</font> companies for <font color="blue">cardiovascular</font> <font color="blue"><font color="blue">indication</font>s</font>;     however, there is no guarantee that any <font color="blue">such company will</font> be interested in     licensing iroxanadine from us or on terms that are favorable to us</td>
    </tr>
    <tr>
      <td>Bimoclomol has <font color="blue">been tested</font> in two <font color="blue">Phase II </font><font color="blue"><font color="blue">clinical trial</font>s</font> where it was     shown  to  be  safe,  but  where it did not show efficacy for diabetic     <font color="blue">neuropathy</font>, the <font color="blue">indication</font> for which it was tested</td>
    </tr>
    <tr>
      <td>We intend to develop     this compound for other therapeutic <font color="blue"><font color="blue">indication</font>s</font>; <font color="blue">however there</font> can be no     guarantee that this <font color="blue">compound will</font> be <font color="blue">effective</font> in treating any diseases</td>
    </tr>
    <tr>
      <td>In     addition, the FDA may require us to perform new safety <font color="blue"><font color="blue">clinical trial</font>s</font>,     <font color="blue">which would</font> be expensive and time consuming and would delay <font color="blue">development</font> of     bimoclomol</td>
    </tr>
    <tr>
      <td>There is no guarantee that any <font color="blue">additional</font> <font color="blue"><font color="blue">clinical trial</font>s</font> will     be successful or that the FDA <font color="blue">will approve</font> any of these products and allow     us to <font color="blue">begin selling them</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Obesity and Type </font>2 Diabetes Laboratory May Not Be Able to Develop     Products          In order to develop <font color="blue">new obesity</font> and type 2 diabetes products, we will     first need to identify <font color="blue">appropriate drug targets</font> and pathways</td>
    </tr>
    <tr>
      <td>We are using     novel RNAi-based <font color="blue">techniques</font> to <font color="blue">accelerate</font> this process, but there is no     assurance that these <font color="blue">techniques</font> will <font color="blue">accelerate</font> our work or that we will be     able to identify <font color="blue">highly promising targets</font> or <font color="blue">pathways using</font> these <font color="blue">techniques</font>     or otherwise</td>
    </tr>
    <tr>
      <td>Even if we are successful in identifying these targets or     pathways, we will need to then develop <font color="blue">proprietary molecules</font> that are safe     and  <font color="blue">effective</font>  against these targets</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> process and the     <font color="blue">clinical testing</font> of our <font color="blue">potential products</font> will take a <font color="blue">lengthy period</font> of     time  and  involve <font color="blue">expenditures</font> <font color="blue">substantially</font> in excess of our current     <font color="blue">financial resources</font> that are available for this purpose</td>
    </tr>
    <tr>
      <td>We are currently     seeking a strategic alliance with a major <font color="blue">pharmaceutical</font> or bio<font color="blue">technology</font>     company to complete the <font color="blue">development</font>, <font color="blue">clinical testing</font> and <font color="blue">manufacturing</font> and     marketing of our <font color="blue">potential obesity</font> and type 2 diabetes products, which are     at an <font color="blue">early stage</font> of <font color="blue">development</font>, but we may not be able to <font color="blue">secure such</font> a     strategic  <font color="blue">partner on attractive terms</font> or at all</td>
    </tr>
    <tr>
      <td>Accordingly, we will be heavily <font color="blue"><font color="blue">dependent</font> on</font> the prior experience     and <font color="blue">current efforts</font> of Dr</td>
    </tr>
    <tr>
      <td>Michael P Czech, the Chairman of our Scientific     Advisory  Board,  Dr</td>
    </tr>
    <tr>
      <td>Mark A Tepper, our Senior Vice President — Drug     Discovery, in <font color="blue">establishing</font> our scientific goals and strategies</td>
    </tr>
    <tr>
      <td>We Will Be Reliant Upon SynthRx to Develop and Commercialize Flocor          In June 2004, we licensed Flocor and our other co-polymer <font color="blue">technologies</font>     to  SynthRx  and acquired a 19dtta9prca equity interest in that newly formed     bio<font color="blue">pharmaceutical</font> company</td>
    </tr>
    <tr>
      <td>SynthRx has only limited <font color="blue">financial resources</font> and     will  have  to either raise <font color="blue">significant</font> <font color="blue"><font color="blue">additional</font> capital</font> or secure a     licensee   or  strategic  partner  to  complete  the  <font color="blue">development</font>  and     <font color="blue">commercialization</font> of Flocor and these other <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We are not aware     that SynthRx has any <font color="blue">commitments</font> from <font color="blue">third parties</font> to provide the capital     that it will require, and there can be no assurance that it will be able to     obtain this capital or a licensee or <font color="blue">strategic partner</font> on satisfactory terms     or at all</td>
    </tr>
    <tr>
      <td>Our prior <font color="blue">Phase III </font><font color="blue">clinical trial</font> of Flocor for the treatment of     <font color="blue">sickle cell disease patients</font> experiencing an acute vaso-occlusive crisis did     not achieve its <font color="blue">primary objective</font></td>
    </tr>
    <tr>
      <td>However, in this study, for patients     15 years of age or younger, the number of patients achieving a resolution of     crisis was higher for Flocor-treated <font color="blue">patients at</font> all time <font color="blue">periods than</font> for     placebo-treated patients, which may indicate that future <font color="blue"><font color="blue">clinical trial</font>s</font>     <font color="blue">should focus on juvenile patients</font></td>
    </tr>
    <tr>
      <td><font color="blue">Generating </font><font color="blue">sufficient data</font> to seek FDA     approval for Flocor will require <font color="blue"><font color="blue">additional</font> clinical studies which</font> have not     <font color="blue">yet been funded</font> or <font color="blue">commenced by</font> SynthRx, and those studies will entail     substantial time and expense for                                         17       _________________________________________________________________    [62]Table of <font color="blue">Contents       </font>SynthRx</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of Flocor involves obtaining <font color="blue">new raw drug</font> substance and     a supply of the <font color="blue"><font color="blue">purified drug</font> from</font> the raw drug substance, which requires     <font color="blue">specialized equipment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Should SynthRx </font>encounter <font color="blue">difficult</font>y in obtaining the     <font color="blue">purified drug</font> substance in <font color="blue">sufficient amounts</font> and at acceptable prices,     SynthRx may be unable to complete the <font color="blue">development</font> or <font color="blue">commercialization</font> of     Flocor on a <font color="blue">timely basis</font> or at all</td>
    </tr>
    <tr>
      <td>We Are Subject to Intense Competition That Could Materially Impact Our     Operating Results          We and our <font color="blue">strategic partner</font>s or licensees may be unable to compete     <font color="blue">successfully</font> against our current or future <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font>,     bio<font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> industry is <font color="blue">characterized by intense</font>     <font color="blue">competition</font> and rapid and <font color="blue">significant</font> <font color="blue">technological</font> advancements</td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>companies, research <font color="blue">institutions</font> and <font color="blue">universities</font> are working in a number of     areas similar to our <font color="blue">primary fields</font> of interest to develop <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>There  also  is intense <font color="blue">competition</font> among companies seeking to acquire     products that already are being marketed</td>
    </tr>
    <tr>
      <td>Many of the <font color="blue">companies with which</font>     we compete have or are likely to have <font color="blue">substantially</font> greater research and     product <font color="blue">development</font> capabilities and financial, technical, scientific,     <font color="blue">manufacturing</font>, marketing, distribution and other <font color="blue">resources than at least</font>     some of our present or future <font color="blue">strategic partner</font>s or licensees</td>
    </tr>
    <tr>
      <td>As a result, these <font color="blue">competitors</font> may:       •   Succeed in developing <font color="blue">competitive</font> products sooner than us or our     <font color="blue">strategic partner</font>s or licensees</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Obtain FDA </font>and other <font color="blue"><font color="blue">regulatory</font> approval</font>s for their products before     approval of any of our products</td>
    </tr>
    <tr>
      <td>•   Obtain patents that block or <font color="blue">otherwise inhibit</font> the <font color="blue">development</font> and     <font color="blue">commercialization</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>•   Develop products that are safer or more <font color="blue">effective</font> than our products</td>
    </tr>
    <tr>
      <td>•   Devote <font color="blue">greater resources</font> to marketing or selling their products</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Introduce </font>or adapt more quickly to new <font color="blue">technologies</font> or scientific     advances</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Introduce </font>products that render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td>•   Withstand price <font color="blue">competition</font> more <font color="blue">successfully</font> than us or our strategic     partners or licensees</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Negotiate </font>third-party strategic alliances or licensing <font color="blue"><font color="blue">arrangement</font>s</font>     more <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>•   Take advantage of other <font color="blue">opportunities</font> more readily</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">medical <font color="blue">institutions</font></font> and <font color="blue"><font color="blue">pharmaceutical</font> companies</font> are     seeking to develop products <font color="blue">based on</font> gene silencing <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>    working in this area include Sirna Therapeutics, Alnylam Pharmaceuticals,     Acuity Pharmaceuticals, Nastech Pharmaceutical Company Inc, Nucleonics,     Inc,  Benitec  Ltd</td>
    </tr>
    <tr>
      <td>and a number of the <font color="blue">multinational</font> <font color="blue">pharmaceutical</font>     companies</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">products currently</font> are being <font color="blue">marketed by</font> a variety of     the <font color="blue">multinational</font> or other <font color="blue"><font color="blue">pharmaceutical</font> companies</font> for treating type II     diabetes, including <font color="blue">among others</font> the <font color="blue">diabetes drugs</font> Avandia^® by Glaxo     SmithKline PLC, Actos^® by Eli Lilly &amp; Co, Glucophage^® by Bristol-Myers     Squibb  Co, Symlin^® by Amylin Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>and Starlix^® by     Novartis and the <font color="blue">obesity drugs</font> Acomplia^® by Sanofi-Aventis SA, Xenical^® by     F Hoffman-La Roche Ltd</td>
    </tr>
    <tr>
      <td>and Meridia^® by <font color="blue">Abbott Laboratories</font></td>
    </tr>
    <tr>
      <td>Many major     <font color="blue"><font color="blue">pharmaceutical</font> companies</font> are <font color="blue">also seeking</font> to develop <font color="blue">new therapies</font> for these     disease <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font>developing HIV vaccines that <font color="blue">could compete</font>     with our HIV vaccine <font color="blue">technology</font> include Merck, VaxGen, Inc, AlphaVax, Inc</td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________    [63]Table of <font color="blue">Contents       </font>          Currently, Rilutek^®, which was developed by Aventis Pharma AG, is     the only drug of which we are aware that has <font color="blue">been <font color="blue">approved by</font></font> the FDA for     the treatment <font color="blue">of ALS Other </font>companies are working to develop <font color="blue">pharmaceutical</font>s     to treat ALS, including Aeolus Pharmaceuticals, Ono Pharmaceuticals, Trophos     SA, FaustPharmaceuticals SA and Oxford BioMedica plc</td>
    </tr>
    <tr>
      <td>In addition, ALS     belongs to a family of diseases called neurodegenerative diseases, which     includes  Alzheimer’s,  Parkinson’s  and  Huntington’s disease</td>
    </tr>
    <tr>
      <td>Due to     <font color="blue">similarities</font>  between  these diseases, a new treatment for one ailment     <font color="blue">potentially</font> could be useful for treating others</td>
    </tr>
    <tr>
      <td>There are many companies     that are producing and developing drugs used to <font color="blue">treat neurodegenerative</font>     diseases other than ALS, including Amgen, Inc, Cephalon, Inc, Ceregene,     Inc,  Elan Pharmaceuticals, plc, H Lundbeck A/S, Phytopharm plc, and     Schwarz Pharma AG          Although we do not expect Flocor to have direct <font color="blue">competition</font> from other     products  currently  available  or that we are aware of that are being     developed related to Flocor’s ability to <font color="blue">reduce blood viscosity</font> in the     <font color="blue">cardiovascular</font> area, there are a number of <font color="blue">anticoagulant products</font> that     Flocor would have to <font color="blue">compete against</font>, such as tissue plasminogen activator,     or t-PA, and streptokinase (blood clot dissolving enzymes) as well as blood     thinners  such  as  heparin and coumatin, even though Flocor acts by a     <font color="blue">different</font> mechanism to <font color="blue">prevent damage due</font> to <font color="blue">blood coagulation</font></td>
    </tr>
    <tr>
      <td>In the     sickle cell disease area, Flocor <font color="blue">would <font color="blue">compete against</font> companies</font> that are     developing or marketing other products to treat sickle cell disease, such as     Droxia^® (hydroxyurea) <font color="blue">marketed by</font> Bristol-Myers Squibb Co</td>
    </tr>
    <tr>
      <td>and Dacogen^tm,     which is being developed by SuperGen, Inc</td>
    </tr>
    <tr>
      <td>Our TranzFect <font color="blue">technology</font> will     <font color="blue">compete against</font> a number of companies that have developed adjuvant products,     such as the adjuvant QS-21^tm <font color="blue">marketed by</font> Antigenics, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">adjuvants</font>     <font color="blue">marketed by</font> <font color="blue">Corixa Corp</font></td>
    </tr>
    <tr>
      <td>We Do Not Have the Ability to Manufacture Any of Our Products and Will Need     to  Rely  upon  Third  Parties for the Manufacture of Our Clinical and     Commercial Product Supplies          We do not currently have the <font color="blue">facilities</font> or expertise to <font color="blue">manufacture</font> any     of the clinical or <font color="blue">commercial supplies</font> of any of our products, including the     supply of <font color="blue">arimoclomol</font> used in our <font color="blue">Phase II </font><font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Accordingly, we     are and will be <font color="blue">dependent</font> upon contract <font color="blue">manufacture</font>rs or our strategic     <font color="blue">alliance partners</font> to <font color="blue">manufacture</font> these supplies, or we will need to acquire     the ability to <font color="blue">manufacture</font> these supplies ourselves, <font color="blue">which could</font> be very     <font color="blue">difficult</font>,  time-consuming  and costly</td>
    </tr>
    <tr>
      <td>We have a <font color="blue">manufacturing</font> supply     <font color="blue">arrangement</font> in place with respect to the <font color="blue">clinical supplies</font> for both the     <font color="blue">Phase IIa </font>and <font color="blue">Phase IIb </font>trials for <font color="blue">arimoclomol</font> for ALS We do not otherwise     have <font color="blue">manufacturing</font> supply <font color="blue"><font color="blue">arrangement</font>s</font> for our other product <font color="blue">candidates</font>,     including any of the licensed RNAi <font color="blue">technology</font>, the other drug <font color="blue">candidates</font>     acquired from Biorex or, with the exception of the <font color="blue">clinical supplies</font> for the     current Phase I trial, the HIV vaccine product that utilizes the HIV vaccine     <font color="blue">technology</font> that we have <font color="blue">licensed from</font> UMMS There can be no assurance that     we will be able to secure needed <font color="blue">manufacturing</font> supply <font color="blue"><font color="blue">arrangement</font>s</font>, or     acquire the ability to <font color="blue">manufacture</font> the products ourselves, on attractive     terms or at all</td>
    </tr>
    <tr>
      <td>Delays in, or a failure to, secure these <font color="blue"><font color="blue">arrangement</font>s</font> or     <font color="blue">abilities could</font> have a <font color="blue">materially</font> adverse effect on our ability to complete     the <font color="blue">development</font> of our products or to <font color="blue">commercialize them</font></td>
    </tr>
    <tr>
      <td>We May Be Unable to Protect Our Intellectual Property Rights, Which Could     Adversely Affect the Value of Our Assets          We believe that obtaining and maintaining patent and other <font color="blue">intellectual</font>     <font color="blue">property rights</font> for our <font color="blue">technologies</font> and <font color="blue">potential products</font> is critical to     <font color="blue">establishing</font> and maintaining the value of our assets and our business</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  believe that we have <font color="blue">significant</font> <font color="blue">patent coverage</font> for the     <font color="blue">technologies</font>  that  we  acquired  from  Biorex  and  for our TranzFect     <font color="blue">technologies</font>, there can be no assurance that this <font color="blue">coverage will</font> be broad     enough to prevent <font color="blue">third parties</font> from developing or <font color="blue">commercializing</font> similar     or identical <font color="blue">technologies</font>, that the validity of our <font color="blue">patents will</font> be upheld     if challenged by <font color="blue">third parties</font> or that our <font color="blue">technologies</font> will not be deemed     to  infringe  the  <font color="blue">intellectual</font>  property  rights of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In     particular,  although we <font color="blue">conducted certain due diligence</font> regarding the     patents and <font color="blue">patent <font color="blue">applications</font></font> acquired from Biorex and received certain     <font color="blue">representations</font>  and  warranties  from  Biorex  in <font color="blue"><font color="blue">connection</font> with</font> the     <font color="blue">acquisition</font>, the patents and <font color="blue">patent <font color="blue">applications</font></font> acquired from Biorex were     issued or filed, as applicable, prior to our <font color="blue">acquisition</font> and thus there can     be no assurance that the validity, enforceability and ownership of those     patents  and <font color="blue">patent <font color="blue">applications</font></font> will be upheld if <font color="blue">challenged by third</font>     parties</td>
    </tr>
    <tr>
      <td>We have a nonexclusive license to a patent owned by UMMS and the     <font color="blue">Carnegie Institution of Washington </font>that claims <font color="blue">various aspects</font> of gene     silencing, or genetic inhibition by double-stranded RNA, but there can be no     assurance that this <font color="blue">patent will withstand possible</font>                                         19       _________________________________________________________________    [64]Table of <font color="blue">Contents       </font>third-party  <font color="blue">challenges</font>  or  otherwise  protect  our <font color="blue">technologies</font> from     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>The medical <font color="blue">applications</font> of the gene silencing <font color="blue">technology</font> and     the other <font color="blue">technologies</font> that we have <font color="blue">licensed from</font> the UMMS also are claimed     in a number of pending <font color="blue">patent <font color="blue">applications</font></font>, but there can be no assurance     that these <font color="blue">applications</font> will result in any <font color="blue">issued patents</font> or that those     <font color="blue">patents will</font> withstand third-party <font color="blue">challenges</font> or protect our <font color="blue">technologies</font>     from <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td>Moreover, we are aware of <font color="blue">at least one</font> other issued United     States  patent  claiming  broad <font color="blue">applications</font> for RNAi, and many patent     <font color="blue">applications</font> covering <font color="blue">different</font> methods and <font color="blue">compositions</font> in the field of     RNAi  <font color="blue">therapeutics</font> have been and are expected to be filed, and certain     <font color="blue">organizations</font> or <font color="blue">researchers may</font> hold or seek to obtain patents that could     make it more <font color="blue">difficult</font> or impossible for us to develop products <font color="blue">based on</font> the     gene silencing <font color="blue">technology</font> that we have licensed</td>
    </tr>
    <tr>
      <td>We are aware that at least     one of our <font color="blue">competitors</font> is <font color="blue">seeking <font color="blue">patent coverage</font></font> in the RNAi field that     <font color="blue">could restrict</font> our ability to develop certain RNAi-based <font color="blue">therapeutics</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation brought by us</font> to protect our <font color="blue"><font color="blue">intellectual</font> property</font>     rights or by <font color="blue">third parties</font> asserting <font color="blue"><font color="blue">intellectual</font> property</font> rights against     us, or <font color="blue">challenging</font> our patents, could be costly and have a material adverse     effect  on  our operating results or <font color="blue">financial condition</font>, make it more     <font color="blue">difficult</font> for us to <font color="blue">enter into</font> strategic alliances with <font color="blue">third parties</font> to     develop our products, or discourage our <font color="blue">existing licensees from continuing</font>     their <font color="blue">development</font> work on our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">patent coverage</font> is     insufficient to prevent <font color="blue">third parties</font> from developing or <font color="blue">commercializing</font>     similar or identical <font color="blue">technologies</font>, the value of our assets is likely to be     <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely affect</font>ed</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">sponsoring research at</font> UMMS and <font color="blue">Massachusetts General Hospital </font>    under  <font color="blue"><font color="blue">agreement</font>s</font>  that  <font color="blue">give us certain rights</font> to acquire licenses to     <font color="blue">inventions</font>, if any, that arise from that research, and we may <font color="blue">enter into</font>     <font color="blue">additional</font> research <font color="blue"><font color="blue">agreement</font>s</font> with those <font color="blue">institutions</font>, or others, in the     future</td>
    </tr>
    <tr>
      <td>We also have a <font color="blue">collaboration</font> and <font color="blue">invention disclosure</font> <font color="blue"><font color="blue">agreement</font> with</font>     UMMS under which UMMS has agreed to disclose to us certain <font color="blue">inventions</font> it     makes  and to give us an option to <font color="blue">negotiate licenses</font> to the disclosed     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>There can be no assurance, however, that any such <font color="blue">inventions</font>     will arise, that we will be able to acquire licenses to any <font color="blue">inventions</font> under     satisfactory terms or at all, or that any <font color="blue">licenses will</font> be useful to us     <font color="blue">commercially</font></td>
    </tr>
    <tr>
      <td><font color="blue">We May Incur Substantial Costs </font>from Future Clinical Testing or <font color="blue">Product     </font>Liability Claims          If any of our products are alleged to be defective, they <font color="blue">may expose us</font>     to claims for <font color="blue">personal injury by patients</font> in <font color="blue"><font color="blue">clinical trial</font>s</font> of our products     or  by  <font color="blue">patients using</font> our <font color="blue">commercially</font> marketed products</td>
    </tr>
    <tr>
      <td>Even if the     <font color="blue">commercialization</font> of one or more of our products is <font color="blue">approved by</font> the FDA,     users may claim that <font color="blue">such products</font> caused <font color="blue">unintended adverse effects</font></td>
    </tr>
    <tr>
      <td>We     currently do not carry <font color="blue">product <font color="blue">liability insurance</font> covering</font> the commercial     marketing of these products</td>
    </tr>
    <tr>
      <td>We have obtained <font color="blue">clinical trial</font> insurance for     our recently-initiated <font color="blue">Phase IIa </font><font color="blue">clinical trial</font> with <font color="blue">arimoclomol</font> for the     treatment  of ALS and will seek to obtain such insurance for any other     <font color="blue"><font color="blue">clinical trial</font>s</font> that we conduct, including the planned <font color="blue">Phase IIb </font>clinical     trial for <font color="blue">arimoclomol</font>, as well as <font color="blue">liability insurance</font> for any products that     we market, although there can be no assurance that we will be able to obtain     <font color="blue"><font color="blue">additional</font> insurance</font> in the amounts we seek or at all</td>
    </tr>
    <tr>
      <td>We anticipate that     our licensees who are developing our <font color="blue">products will</font> carry <font color="blue">liability insurance</font>     covering the <font color="blue">clinical testing</font> and marketing of those products</td>
    </tr>
    <tr>
      <td>However, if     someone  asserts a claim <font color="blue">against us</font> and our insurance or the insurance     coverage  of  our  licensees or if their other <font color="blue">financial resources</font> are     inadequate to cover a successful claim, <font color="blue">such successful</font> claim could have a     material  adverse  effect  on  our  <font color="blue">financial condition</font> or cause us to     discontinue <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Even if claims asserted <font color="blue">against us</font> are <font color="blue">unsuccessful</font>,     they may divert <font color="blue">management</font>’s attention from our <font color="blue">operations</font> and we may have     to incur substantial costs to <font color="blue">defend such</font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with <font color="blue">Requirements of Section </font>404 of the Sarbanes-Oxley Act of     2002 Will Increase Our Costs and Require Additional Management Resources,     and We May Not Successfully Comply          As <font color="blue">directed by</font> Section 404 of the Sarbanes-Oxley Act of 2002, <font color="blue">the SEC     </font><font color="blue">adopted rules</font> requiring <font color="blue">public companies</font> to include a report of <font color="blue">management</font>     on the company’s <font color="blue"><font color="blue">internal controls over</font> financial</font> reporting in their annual     reports  on  Form 10-K In addition, the in<font color="blue">dependent</font> registered public     <font color="blue">accounting firm auditing</font> the company’s <font color="blue">financial statements</font> must attest to     and report on <font color="blue">management</font>’s assessment of the <font color="blue"><font color="blue">effective</font>ness</font> of the company’s     <font color="blue"><font color="blue">internal controls over</font> financial</font> reporting</td>
    </tr>
    <tr>
      <td><font color="blue">Although the SEC </font>has postponed     the <font color="blue"><font color="blue">effective</font>ness</font> of this <font color="blue">requirement several times</font>, if the SEC does not     postpone or <font color="blue">otherwise alter</font> the requirement again, then we expect that it     <font color="blue">will first apply</font> to our annual report on Form 10-K for our <font color="blue">fiscal year</font>     ending  <font color="blue">December </font>31, 2006</td>
    </tr>
    <tr>
      <td>If we are required to comply, we will incur     <font color="blue">significant</font> legal, accounting, and other expenses and <font color="blue">compliance will occupy</font>     a substantial                                         20       _________________________________________________________________    [65]Table of <font color="blue">Contents       </font>amount of time of our board of <font color="blue">directors</font> and <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainty </font>exists     regarding our ability to <font color="blue">comply with</font> these <font color="blue">requirements</font> by the SEC’s current     <font color="blue">deadlines</font></td>
    </tr>
    <tr>
      <td>If we are unable to complete the required assessment as to the     adequacy  of our internal control reporting or if we conclude that our     <font color="blue"><font color="blue">internal controls over</font> financial</font> reporting are not <font color="blue">effective</font> or if our     in<font color="blue">dependent</font> registered public accounting firm is unable to <font color="blue">provide us with</font>     an unqualified report as to the <font color="blue"><font color="blue">effective</font>ness</font> of our <font color="blue">internal controls over</font>     financial reporting as of <font color="blue">December </font>31, 2006 and <font color="blue">future year</font> ends, investors     <font color="blue">could lose confidence</font> in the <font color="blue">reliability</font> of our financial reporting</td>
    </tr>
    <tr>
      <td>In     addition, while we plan to expand our staff to assist in <font color="blue">complying with</font> the     <font color="blue">additional</font> <font color="blue">requirements</font> when and if they <font color="blue">become applicable</font>, we <font color="blue">may encounter</font>     substantial <font color="blue">difficult</font>y attracting qualified staff with requisite experience     due  to  the  high  level  of  <font color="blue">competition</font>  for  experienced financial     <font color="blue">professionals</font></td>
    </tr>
    <tr>
      <td>Our  Anti-Takeover Provisions May Make It More Difficult to Change Our     Management or May Discourage Others From Acquiring Us and Thereby Adversely     Affect Stockholder Value          We have a <font color="blue">stockholder rights</font> plan and provisions in our bylaws that may     discourage  or prevent a person or group from acquiring us without the     approval of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>The intent of the <font color="blue">stockholder rights</font>     plan and our <font color="blue">bylaw provisions</font> is to protect our <font color="blue">stockholders</font>’ interests by     <font color="blue">encouraging anyone seeking control</font> of our company to <font color="blue">negotiate with</font> our     board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>We have a <font color="blue">classified board</font> of <font color="blue">directors</font>, which requires that at least     two stockholder meetings, instead of one, will be required to effect a     change in the <font color="blue">majority control</font> of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>This provision     applies to <font color="blue">every election</font> of <font color="blue">directors</font>, not just an election occurring after     a change in control</td>
    </tr>
    <tr>
      <td>The classification of our board increases the amount of     time it takes to change <font color="blue">majority control</font> of our board of <font color="blue">directors</font> and may     cause our <font color="blue">potential purchase</font>rs to <font color="blue">lose interest</font> in the <font color="blue">potential purchase</font> of     us, regardless of whether our <font color="blue">purchase would</font> be <font color="blue">beneficial</font> to us or our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">additional</font> time and cost to change a majority of the     members of our board of <font color="blue">directors</font> makes it more <font color="blue">difficult</font> and <font color="blue">may discourage</font>     our existing <font color="blue">stockholders</font> from seeking to change our existing <font color="blue">management</font> in     order to change the <font color="blue">strategic direction</font> or <font color="blue">operational performance</font> of our     company</td>
    </tr>
    <tr>
      <td>Our bylaws provide that <font color="blue">directors</font> may only be removed for cause by the     <font color="blue">affirmative vote</font> of the holders of at least a majority of the outstanding     shares  of  our  <font color="blue">capital stock then entitled</font> to vote at an election of     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">provision prevents</font> <font color="blue">stockholders</font> from removing any incumbent     <font color="blue">director without</font> cause</td>
    </tr>
    <tr>
      <td>Our bylaws <font color="blue">also provide</font> that a stockholder must give     us at least 120 days notice of a proposal or <font color="blue">director nomination</font> that such     stockholder desires to <font color="blue">present at</font> any <font color="blue">annual meeting</font> or <font color="blue">special meeting</font> of     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">provision prevents</font> a <font color="blue">stockholder from</font> making a proposal     or <font color="blue">director nomination</font> at a <font color="blue">stockholder meeting without us</font> having advance     notice of that proposal or <font color="blue">director nomination</font></td>
    </tr>
    <tr>
      <td>This could make a change in     control more <font color="blue">difficult</font> by providing our <font color="blue">directors</font> with more time to prepare     an opposition to a proposed change in control</td>
    </tr>
    <tr>
      <td>By making it more <font color="blue">difficult</font>     to remove or install new <font color="blue">directors</font>, the foregoing <font color="blue">bylaw provisions</font> may also     make  our  existing  <font color="blue">management</font>  less  responsive  to the views of our     <font color="blue">stockholders</font>  with  respect to our <font color="blue">operations</font> and other <font color="blue">issues such as</font>     <font color="blue">management</font> selection and <font color="blue">management</font> compensation</td>
    </tr>
    <tr>
      <td>Our Outstanding Options and Warrants and the Registrations of Our Shares     Issued in the <font color="blue">Global Genomics </font>Merger and Our Recent Private Financings May     Adversely Affect the Trading Price of Our Common Stock          As of <font color="blue">December </font>31, 2005, there were <font color="blue">outstanding <font color="blue">stock options</font></font> and     warrants to purchase <font color="blue">approximately</font> 24dtta7 million shares of our <font color="blue">common stock</font>     at <font color="blue">exercise price</font>s ranging from dlra0dtta20 to dlra2dtta73 per share</td>
    </tr>
    <tr>
      <td>Our outstanding     options and warrants could <font color="blue">adversely affect</font> our ability to obtain future     financing or engage in <font color="blue">certain mergers</font> or other <font color="blue">transaction</font>s, since the     holders of options and warrants can be expected to <font color="blue">exercise them at</font> a time     when we may be able to obtain <font color="blue"><font color="blue">additional</font> capital</font> through a new offering of     <font color="blue">securities on terms</font> more favorable to us than the terms of outstanding     options and warrants</td>
    </tr>
    <tr>
      <td>For the life of the options and warrants, the holders     have the <font color="blue">opportunity</font> to <font color="blue">profit from</font> a rise in the <font color="blue">market price</font> of our common     <font color="blue">stock without</font> assuming the risk of ownership</td>
    </tr>
    <tr>
      <td>To the extent the trading     price of our <font color="blue">common stock</font> at the time of exercise of any <font color="blue">such options</font> or     <font color="blue">warrants exceeds</font> the <font color="blue">exercise price</font>, such exercise will also have a dilutive     effect on our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, warrants issued in <font color="blue"><font color="blue">connection</font> with</font>     our <font color="blue">financings</font> in 2003 contain anti-dilution provisions that are triggered     <font color="blue">upon certain events</font>, including any issuance of <font color="blue">securities by us</font> below the     <font color="blue">market price</font></td>
    </tr>
    <tr>
      <td>In the event that those anti-dilution provisions are triggered     by us in the future, we would be required to reduce the <font color="blue">exercise price</font>, and     increase the number of <font color="blue">shares underlying</font>,                                         21       _________________________________________________________________    [66]Table of <font color="blue">Contents       </font>those warrants, <font color="blue">which would</font> have a dilutive effect on our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In August 2003, we <font color="blue">registered with</font> the SEC for resale by the holders a     total of 14cmam408cmam252 shares of our outstanding <font color="blue">common stock</font> and an <font color="blue">additional</font>     3cmam848cmam870 shares of our <font color="blue">common stock</font> <font color="blue">issuable upon</font> exercise of outstanding     options and warrants, which shares and options and warrants were issued     primarily  in  <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue">merger with</font> <font color="blue">Global Genomics </font>and the     dlra5dtta4 million private <font color="blue">equity financing</font> that we completed in May 2003</td>
    </tr>
    <tr>
      <td>In     <font color="blue">December </font>2003, we registered a total of 6cmam113cmam448 shares of our common     stock, consisting of the 5cmam175cmam611 shares issued, or that are <font color="blue">issuable upon</font>     exercise of the warrants issued, in <font color="blue"><font color="blue">connection</font> with</font> the dlra8dtta7 million private     <font color="blue">equity financing</font> that we completed in <font color="blue">September </font>2003, and an <font color="blue">additional</font>     937cmam837 shares of our <font color="blue">common stock</font> that we issued, or that are <font color="blue">issuable upon</font>     the exercise of warrants that we issued, to certain other <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In     November 2004, we registered 4cmam000cmam000 shares of our <font color="blue">common stock</font> and an     <font color="blue">additional</font> 3cmam080cmam000 shares of our <font color="blue">common stock</font> <font color="blue">issuable upon</font> the exercise     of warrants in <font color="blue"><font color="blue">connection</font> with</font> the dlra4cmam000cmam000 private <font color="blue">equity financing</font> that     we completed in October 2004, and an <font color="blue">additional</font> 1cmam550cmam000 shares of our     <font color="blue">common stock</font> issued or <font color="blue">issuable upon</font> exercise of warrants to other third     parties</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2005, we registered 17cmam334cmam494 shares of our common     stock and an <font color="blue">additional</font> 9cmam909cmam117 shares of our <font color="blue">common stock</font> <font color="blue">issuable upon</font>     the exercise of warrants in <font color="blue"><font color="blue">connection</font> with</font> the dlra21dtta3 million private equity     financing that we completed in January 2005</td>
    </tr>
    <tr>
      <td>In April 2006, we expect to     file a <font color="blue">registration statement</font> to register 10cmam650cmam794 shares of our common     stock and an <font color="blue">additional</font> 5cmam325cmam397 shares of our <font color="blue">common stock</font> <font color="blue">issuable upon</font>     the exercise of warrants in <font color="blue"><font color="blue">connection</font> with</font> the dlra13dtta4 million private equity     financing that we completed in March 2006</td>
    </tr>
    <tr>
      <td>Both the <font color="blue">availability</font> for public     resale of these various shares and the <font color="blue">actual resale</font> of these <font color="blue">shares could</font>     <font color="blue">adversely affect</font> the <font color="blue">trading price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We May Issue Preferred Stock in the Future, and the Terms of the Preferred     Stock May Reduce the Value of Our Common Stock          We are authorized to issue up to 5cmam000cmam000 shares of <font color="blue">preferred stock</font> in     one or more series</td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> may determine the terms of future     <font color="blue">preferred stock</font> offerings without further action by our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we     issue <font color="blue">preferred stock</font>, it <font color="blue">could affect</font> your rights or reduce the value of     our outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In particular, specific rights granted to     <font color="blue">future holders</font> of <font color="blue">preferred stock</font> may include voting rights, preferences as     to dividends and liquidation, conversion and redemption rights, sinking fund     provisions, and <font color="blue">restrictions on</font> our ability to <font color="blue">merge with</font> or sell our assets     to a <font color="blue">third party</font></td>
    </tr>
    <tr>
      <td>Changes in Stock Option Accounting Rules May Adversely Impact Our Reported     Operating Results, Our Stock Price and Our Competitiveness in the Employee     Marketplace          In <font color="blue">December </font>2004, the <font color="blue">Financial Accounting Standards Board </font>published     new rules that will require companies in 2005 to record all stock-based     <font color="blue">employee compensation as</font> an expense</td>
    </tr>
    <tr>
      <td>The <font color="blue">new rules apply</font> to <font color="blue">stock options</font>     grants, as well as a range of other stock-based compensation <font color="blue"><font color="blue">arrangement</font>s</font>,     including  restricted  share  plans,  performance-based  awards, share     <font color="blue">appreciation rights</font>, and employee share purchase plans</td>
    </tr>
    <tr>
      <td>We will have to     apply the <font color="blue">new financial accounting rules beginning</font> in the <font color="blue">first quarter</font> of     2006</td>
    </tr>
    <tr>
      <td>We  have  depended  in the <font color="blue">past upon compensating</font> our officers,     <font color="blue">directors</font>, employees and <font color="blue">consultants</font> with such stock-based compensation     awards in order to limit our cash <font color="blue">expenditures</font> and to attract and retain     officers, <font color="blue">directors</font>, employees and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>Accordingly, if we continue     to grant <font color="blue">stock options</font> or other stock-based compensation awards to our     officers, <font color="blue">directors</font>, employees, and <font color="blue">consultants</font> after the <font color="blue">new rules apply</font> to     us, our <font color="blue">future earnings</font>, if any, will be reduced (or our <font color="blue">future losses will</font>     be increased) by the <font color="blue">expenses recorded</font> for those grants</td>
    </tr>
    <tr>
      <td>The expenses we may     have to record as a result of <font color="blue">future options grants may</font> be <font color="blue">significant</font> and     may <font color="blue">materially</font> negatively affect our reported financial results</td>
    </tr>
    <tr>
      <td>The adverse     effects that the <font color="blue">new accounting rules may</font> have on our <font color="blue">future financial</font>     <font color="blue">statements should</font> we continue to rely heavily on stock-based compensation     may reduce our stock price and make it more <font color="blue">difficult</font> for us to <font color="blue">attract new</font>     investors</td>
    </tr>
    <tr>
      <td>In addition, reducing our use of stock plans to reward and     <font color="blue">incentivize</font>  our  officers,  <font color="blue">directors</font> and <font color="blue">employees could</font> result in a     <font color="blue">competitive</font> disadvantage to us in the <font color="blue">employee marketplace</font></td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________    [67]Table of <font color="blue">Contents       </font>We May Experience Volatility in Our Stock Price, Which May Adversely Affect     the Trading Price of Our Common Stock          The  <font color="blue">market price</font> of our <font color="blue">common stock</font> has experienced <font color="blue">significant</font>     <font color="blue">volatility</font> in the past and <font color="blue">may continue</font> to experience <font color="blue">significant</font> <font color="blue">volatility</font>     from time to time</td>
    </tr>
    <tr>
      <td>Our stock price has ranged from dlra0dtta21 to dlra3dtta74 per share     over the past <font color="blue">three years</font></td>
    </tr>
    <tr>
      <td>Factors such as the <font color="blue">following may affect such</font>     <font color="blue">volatility</font>:       •   Our quarterly operating results</td>
    </tr>
    <tr>
      <td>•   <font color="blue">Announcements </font>of <font color="blue">regulatory</font> <font color="blue">development</font>s or <font color="blue">technological</font> <font color="blue">innovations</font>     by us or our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>•   <font color="blue">Government </font>regulation of <font color="blue">drug pricing</font></td>
    </tr>
    <tr>
      <td>•   <font color="blue">Developments </font>in patent or other <font color="blue">technology</font> ownership rights</td>
    </tr>
    <tr>
      <td>Other <font color="blue">factors which may affect</font> our stock price are general changes in     the  economy, financial markets or the <font color="blue">pharmaceutical</font> or bio<font color="blue">technology</font>     <font color="blue">industries</font></td>
    </tr>
  </tbody>
</table>